Drua Lawyer loses license over theft of client funds in eastern Iowa
WASHINGTON AP 鈥?This year s Christmas ornament from the White House Historical Association honors the tradition of displaying a gingerbread model of the executive mansion as part of the holiday decorations at 1600 Pennsylvania Ave.The 2022 ornament 鈥?a gingerbread house shaped like the mansion 鈥?honors President Richard Nixon s administration. It was first lady Patricia Nixon who first put a gingerbread house on display in the State Dining Roo
stanley cup m for the holidays. That was long before the talented White House pastry chefs began making hundred-pound replicas of the executive mansion.Now, holiday time at the White House would feel incomplete without one. Initially these were A-frame houses, but now they are actual White Houses, gingerbread houses built in the shape of the White House, Stewart McLaurin, president of the association, told The Associated Press in an interview. The privately funded association began selling the popular annual White House Christmas ornament in 1981.The 2022 ornament shows the north and south fronts of a gingerbread White House that is dec
stanley uk orated with white piping, r
stanley mug ed-and-white candies, gumdrops and candy canes. Each ornament comes with a booklet on the history of that particular presidency, and this year s is gingerbread-scented.The gingerbread White House currently on display for thousands of tourists and guests attending holiday receptions weighs 300 pounds and includes a sugar cookie replica of Philadelphia s Independence Hall, in keeping with f Jmsd YELICH OUT: Christian Yelich will undergo season-ending back surgery Friday
Pharmaceutical com
kubki stanley pany Merck announced Friday that its experimental COVID-19 pill reduced hospitalizations an
stanley thermobecher d deaths by half in people recently infected with the coronavirus.The company said it would soon ask health officials in the U.S. and around the world to authorize its use.Mercks drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic.Merk says 7.3% of patients who received the medicine, called molnupiravir, in an interim analysis were either hospitalized or died through Day 29 following randomization, compared with 14.1% of placebo-treated patients.The trial for the pill looked at non-hospitalized adult patients with laboratory-confirmed mild to moderate COVID-19 who had at least one risk factor associated with poor disease o
stanley cups utcomes and their symptoms started within five days of the randomization.Merck says Molnupiravir is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of the COVID-19 virus. Its been shown to be active in several preclinical models of the virus, including for prophylaxis, treatment, and prevention of transmission, according to Merk. The company says the pill has also been shown to be active against the most common variants.The study was conducted globally, including in more than 170 planned sites in countries including Argentina, Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan, Mexico, Ph